BioSpace News Archive

Vor Bio, a clinical-stage cell and genome engineering company, presented updated clinical data from patients treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel in patients with acute myeloid leukemia.

Cogent Biosciences, Inc., a biotechnology company focused on developing precision therapies for genetically defined diseases, announced the closing of its previously announced upsized underwritten public offering of 12,500,000 shares of its common stock.

Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted four employees nonqualified stock options to purchase 308,000 shares of its common stock with an exercise price of $3.06 per share, which is equal to the closing price of Kezar’s common stock on June 6, 2023, the grant date of the awards.

Labcorp, a leading global life sciences company, announced the following record and distribution dates for the spin-off of Fortrea Holdings Inc., a wholly owned subsidiary of Labcorp.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced it will present data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) in an oral presentation at the International Conference on Malignant Lymphoma (ICML) on June 13–17, 2023.